Investors Face August Deadline in ADMA Biologics Securities Lawsuit
Investors holding ADMA Biologics stock between August 9, 2024, and March 25, 2026, have until August 10, 2026, to seek lead plaintiff status in a pending class action lawsuit. The litigation, filed in the District of New Jersey, centers on allegations of deceptive financial practices and misleading corporate disclosures.
The complaint, Mazzarino v. ADMA Biologics, Inc., et al., alleges that the company and its executives violated federal securities laws by failing to disclose critical information to shareholders. Plaintiffs claim the company utilized channel stuffing to artificially inflate revenue figures and failed to maintain adequate internal controls. Additionally, the lawsuit asserts that ADMA Biologics engaged in undisclosed related-party transactions, rendering their public statements regarding business operations and financial health materially false or lacking a reasonable basis.
Kahn Swick & Foti, LLC, representing the investors, states that these practices led to significant financial losses once the details surfaced in the market. While investors have until the August 10 deadline to request appointment as lead plaintiff, the firm notes that individual investors do not need to serve in this capacity to remain eligible for a potential recovery. Those seeking further information or representation may contact managing partner Lewis Kahn at 1-877-515-1850.
Comments (0)
No comments yet. Be the first!